Martin Dietrich, MD, PhD, separates an agent working in the brain from an agent acting on the brain, and explains that ...
Preview the 2026 International Myeloma Society meeting: the IMS/IMWG cure consensus, plenary session phase 3 trials, and new bispecific/CAR T myeloma findings. The 23rd International Myeloma Society ...
Martin Dietrich, MD, PhD, says he manages neurologic adverse events reactively rather than proactively, because he cannot ...
Fast Track designation supports expedited development of LYT-200 plus an HMA in R/R HR-MDS following prior HMA relapse or ...
Gandara, MD, explains why KRAS G12C predicts immunotherapy benefit in non–small cell lung cancer and what EMPOWER-Lung 1 means for trial design. He noted that most earlier analyses lumped KRAS ...
Immune thrombocytopenia (ITP) is a disease that, a generation ago, left oncologists cycling patients through cyclophosphamide ...
Vargas, MD discusses how his institution builds a safe learning curve for surgeons adopting the subcostal robotic approach to ...
Jeff Sharman, MD, explores how targeted therapies have transformed CLL treatment and what emerging approaches could shape the future of care. Chronic lymphocytic leukemia (CLL) treatment has undergone ...
Overall, tiredness, depression, and poor well-being were the most prevalent moderate-to-severe symptoms across cancer types, reported by 37%, 34%, and 33% of patients, respectively. The median total ...
David DiBardino, MD, explains how a hafnium compound is being tested alongside chemoradiation and durvalumab to address low ...
Nearly 3 years’ follow-up showed cORR 89.8%, median DOR 49.7 months, and median PFS 46.1 months in TKI-naive ROS1+ NSCLC, supporting long-term disease control. Post–ROS1 TKI activity remained ...
The imlunestrant label includes a warning and precaution for embryo-fetal toxicity, and the abemaciclib label includes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results